Gilead Sciences (NASDAQ:GILD) has agreed to invest $300M for a 49.9% stake in privately held Tizona Therapeutics.
GILD has the option to acquire the remainder of the South San Francisco-based cancer immunotherapy developer for $1.25B.
Tizona’s lead candidate is Phase 1-stage TTX-030, an anti-CD39 monoclonal antibody that it is co-developing with AbbVie for the treatment of solid tumors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.